Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, today announced the first results from a collaboration with Insilico Medicine (“Insilico”), a clinical-stage biotechnology company driven by generative AI, focused on rentosertib (ISM001-055), a novel TNIK inhibitor discovered using Insilico’s generative AI approach, in development for the treatment of IPF.